Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)

NCT04424914 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04424914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04424914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GLOBAL PREVALENCE OF TRANSTHYRETIN AMYLOID CARDIOMYOPATHY (ATTR-CM) IN PARTICIPANTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (HFpEF)
Lead sponsor
Pfizer
Phase
Not applicable
Overall status
Terminated
Start date
December 30, 2020
Completion date
June 2, 2023
Enrollment
347 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with preserved ejection fraction, transthyretin amyloid cardiomyopathy